Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy KalVista Pharmaceuticals stock | $27

Learn how to easily invest in KalVista Pharmaceuticals stock.

KalVista Pharmaceuticals, Inc is a biotechnology business based in the US. KalVista Pharmaceuticals shares (KALV) are listed on the NASDAQ and all prices are listed in US Dollars. KalVista Pharmaceuticals employs 70 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in KalVista Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KALV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

KalVista Pharmaceuticals stock price (NASDAQ: KALV)

Use our graph to track the performance of KALV stocks over time.

KalVista Pharmaceuticals shares at a glance

Information last updated 2021-07-30.
Latest market close$27.00
52-week range$9.69 - $43.08
50-day moving average $24.30
200-day moving average $25.94
Wall St. target price$55.43
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.38

Buy KalVista Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy KalVista Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

KalVista Pharmaceuticals price performance over time

Historical closes compared with the close of $27 from 2021-05-28

1 week (2021-07-25) N/A
1 month (2021-07-02) 15.19%
3 months (2021-05-05) 8.26%
6 months (2021-02-01) N/A
1 year (2020-08-01) N/A
2 years (2019-08-01) N/A
3 years (2018-08-01) N/A
5 years (2016-08-01) N/A

KalVista Pharmaceuticals financials

Revenue TTM $3.8 million
Gross profit TTM $-41,286,000
Return on assets TTM -19.86%
Return on equity TTM -27.13%
Profit margin 0%
Book value $10.53
Market capitalisation $504.7 million

TTM: trailing 12 months

Shorting KalVista Pharmaceuticals shares

There are currently 2.0 million KalVista Pharmaceuticals shares held short by investors – that's known as KalVista Pharmaceuticals's "short interest". This figure is 1.8% down from 2.0 million last month.

There are a few different ways that this level of interest in shorting KalVista Pharmaceuticals shares can be evaluated.

KalVista Pharmaceuticals's "short interest ratio" (SIR)

KalVista Pharmaceuticals's "short interest ratio" (SIR) is the quantity of KalVista Pharmaceuticals shares currently shorted divided by the average quantity of KalVista Pharmaceuticals shares traded daily (recently around 330449.07251265). KalVista Pharmaceuticals's SIR currently stands at 5.93. In other words for every 100,000 KalVista Pharmaceuticals shares traded daily on the market, roughly 5930 shares are currently held short.

However KalVista Pharmaceuticals's short interest can also be evaluated against the total number of KalVista Pharmaceuticals shares, or, against the total number of tradable KalVista Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case KalVista Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 KalVista Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.1087% of the tradable shares (for every 100,000 tradable KalVista Pharmaceuticals shares, roughly 109 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against KalVista Pharmaceuticals.

Find out more about how you can short KalVista Pharmaceuticals stock.

KalVista Pharmaceuticals share dividends

We're not expecting KalVista Pharmaceuticals to pay a dividend over the next 12 months.

Have KalVista Pharmaceuticals's shares ever split?

KalVista Pharmaceuticals's shares were split on a 1:14 basis on 21 November 2016. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your KalVista Pharmaceuticals shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for KalVista Pharmaceuticals shares which in turn could have impacted KalVista Pharmaceuticals's share price.

KalVista Pharmaceuticals share price volatility

Over the last 12 months, KalVista Pharmaceuticals's shares have ranged in value from as little as $9.6905 up to $43.0799. A popular way to gauge a stock's volatility is its "beta".

KALV.US volatility(beta: 2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while KalVista Pharmaceuticals's is 1.9954. This would suggest that KalVista Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

KalVista Pharmaceuticals overview

KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts. .

Stocks similar to KalVista Pharmaceuticals

Frequently asked questions

What percentage of KalVista Pharmaceuticals is owned by insiders or institutions?
Currently 6.363% of KalVista Pharmaceuticals shares are held by insiders and 109.489% by institutions.
How many people work for KalVista Pharmaceuticals?
Latest data suggests 70 work at KalVista Pharmaceuticals.
When does the fiscal year end for KalVista Pharmaceuticals?
KalVista Pharmaceuticals's fiscal year ends in April.
Where is KalVista Pharmaceuticals based?
KalVista Pharmaceuticals's address is: 55 Cambridge Parkway, Cambridge, MA, United States, 02142
What is KalVista Pharmaceuticals's ISIN number?
KalVista Pharmaceuticals's international securities identification number is: US4834971032
What is KalVista Pharmaceuticals's CUSIP number?
KalVista Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 141384107

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site